---
title: CDMO Daily News — September 19, 2026
slug: daily-news-2026-09-19-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 19 CDMO daily: Kincell Bio and Cellipont Merge to Form Kincellis Advanced Therapies; Quotient Sciences' AI Algorithm Achieves Pharmacokinetic Target…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-19-cdmo
published_at: 2026-09-19T00:00:41.156Z
last_updated: 2026-09-19T00:01:58.256Z
---

### [Kincell Bio](/companies/kincellbio) and Cellipont Merge to Form Kincellis Advanced Therapies
- [Kincell Bio](/companies/kincellbio) and [Cellipont Bioservices](/companies/cellipont-bioservices) completed merger to create Kincellis Advanced Therapies, a U.S.-based CDMO specializing in cell and advanced therapies.
- Kincellis operates 140,000 sq ft across three U.S. sites (Florida, North Carolina, Texas) with 16 qualified GMP manufacturing suites supporting early development through commercial supply.
- Combined entity has released 150+ GMP batches, supports 10 IND filings in 2026, and employs 200+ staff; merger funded by NewSpring Capital, Kineticos, HealthQuest, and Great Point Partners.

**Operational Impact**

Kincellis' consolidated 16-suite GMP footprint across Florida, North Carolina, and Texas adds dedicated cell-therapy manufacturing capacity for autologous and allogeneic programs, with active support for 10 IND filings and 150+ released batches positioning the merged entity as a scaled competitor in advanced-modality CDMO services.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/kincellis-advanced-therapies-formed-through-kincell-and-cellipont-merger)*

---

### [Quotient Sciences](/companies/quotientsciences)' AI Algorithm Achieves Pharmacokinetic Target in Modified-Release Formulation Study
- AI algorithm selected formulation compositions and doses in a clinical trial, reaching preset pharmacokinetic targets within three dosing periods.
- Algorithm was trained on in vitro release data and retrained during the study using tablet dissolution and PK data from healthy volunteers.
- [Quotient Sciences](/companies/quotientsciences) screened one-third fewer formulations than conventional methods during laboratory screening phase.

**Operational Impact**

[Quotient Sciences](/companies/quotientsciences)' validated AI-guided formulation platform may accelerate drug-product development timelines and reduce formulation screening costs for CDMO clients pursuing modified-release generic and branded programs.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/quotient-sciences-reports-interim-results-from-ai-guided-formulation-study)*

## References

1. [PharmaSource RSS — Kincell Bio and Cellipont Merge to Form Kincellis Advanced Therapies](https://pharmasource.global/content/news/cdmo-news/kincellis-advanced-therapies-formed-through-kincell-and-cellipont-merger)
2. [PharmaSource RSS — Quotient Sciences' AI Algorithm Achieves Pharmacokinetic Target in Modified-Release Formulation Study](https://pharmasource.global/content/news/cdmo-news/quotient-sciences-reports-interim-results-from-ai-guided-formulation-study)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-19-cdmo